DrugRepoBank: a Comprehensive Database and Discovery Platform for Accelerating Drug Repositioning

Overview

Journal Database (Oxford)

Specialty Biology

Date 2024 Jul 12

PMID 38994794

Authors

Yixian Huang

Danhong Dong

Wenyang Zhang

Ruiting Wang

Yang-Chi-Dung Lin

Huali Zuo

Hsi-Yuan Huang

Hsien-Da Huang

Affiliations

Soon will be listed here.

Abstract

In recent years, drug repositioning has emerged as a promising alternative to the time-consuming, expensive and risky process of developing new drugs for diseases. However, the current database for drug repositioning faces several issues, including insufficient data volume, restricted data types, algorithm inaccuracies resulting from the neglect of multidimensional or heterogeneous data, a lack of systematic organization of literature data associated with drug repositioning, limited analytical capabilities and user-unfriendly webpage interfaces. Hence, we have established the first all-encompassing database called DrugRepoBank, consisting of two main modules: the 'Literature' module and the 'Prediction' module. The 'Literature' module serves as the largest repository of literature-supported drug repositioning data with experimental evidence, encompassing 169 repositioned drugs from 134 articles from 1 January 2000 to 1 July 2023. The 'Prediction' module employs 18 efficient algorithms, including similarity-based, artificial-intelligence-based, signature-based and network-based methods to predict repositioned drug candidates. The DrugRepoBank features an interactive and user-friendly web interface and offers comprehensive functionalities such as bioinformatics analysis of disease signatures. When users provide information about a drug, target or disease of interest, DrugRepoBank offers new indications and targets for the drug, proposes new drugs that bind to the target or suggests potential drugs for the queried disease. Additionally, it provides basic information about drugs, targets or diseases, along with supporting literature. We utilize three case studies to demonstrate the feasibility and effectiveness of predictively repositioned drugs within DrugRepoBank. The establishment of the DrugRepoBank database will significantly accelerate the pace of drug repositioning. Database URL: https://awi.cuhk.edu.cn/DrugRepoBank.

Citing Articles

Old drugs, new challenges: reassigning drugs for cancer therapies.

Czechowicz P, Wiech-Walow A, Slawski J, Collawn J, Bartoszewski R Cell Mol Biol Lett. 2025; 30(1):27.

PMID: 40038587 PMC: 11881393. DOI: 10.1186/s11658-025-00710-0.

Storage and Query of Drug Knowledge Graphs Using Distributed Graph Databases: A Case Study.

Han X, Tian Y Bioengineering (Basel). 2025; 12(2).

PMID: 40001634 PMC: 11852034. DOI: 10.3390/bioengineering12020115.

Strategies for robust, accurate, and generalizable benchmarking of drug discovery platforms.

Van Norden M, Mangione W, Falls Z, Samudrala R bioRxiv. 2025; .

PMID: 39764006 PMC: 11702551. DOI: 10.1101/2024.12.10.627863.

NFSA-DTI: A Novel Drug-Target Interaction Prediction Model Using Neural Fingerprint and Self-Attention Mechanism.

Liu F, Xu H, Cui P, Li S, Wang H, Wu Z Int J Mol Sci. 2024; 25(21).

PMID: 39519369 PMC: 11546351. DOI: 10.3390/ijms252111818.

Some Aspects and Convergence of Human and Veterinary Drug Repositioning.

Mag P, Nemes-Terenyi M, Jerzsele A, Matyus P Molecules. 2024; 29(18).

PMID: 39339469 PMC: 11433938. DOI: 10.3390/molecules29184475.

References

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Yin J, Chen Z, You N, Li F, Zhang H, Xue J . VARIDT 3.0: the phenotypic and regulatory variability of drug transporter. Nucleic Acids Res. 2023; 52(D1):D1490-D1502. PMC: 10767864. DOI: 10.1093/nar/gkad818. View

Zhang Y, Zhou Y, Zhou Y, Yu X, Shen X, Hong Y . TheMarker: a comprehensive database of therapeutic biomarkers. Nucleic Acids Res. 2023; 52(D1):D1450-D1464. PMC: 10767989. DOI: 10.1093/nar/gkad862. View

Crisanti M, Wallace A, Kapoor V, Vandermeers F, Dowling M, Pereira L . The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009; 8(8):2221-31. PMC: 3605895. DOI: 10.1158/1535-7163.MCT-09-0138. View

Huang Y, Huang H, Chen Y, Lin Y, Yao L, Lin T . A Robust Drug-Target Interaction Prediction Framework with Capsule Network and Transfer Learning. Int J Mol Sci. 2023; 24(18). PMC: 10531393. DOI: 10.3390/ijms241814061. View

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M . KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2020; 49(D1):D545-D551. PMC: 7779016. DOI: 10.1093/nar/gkaa970. View

Tsubaki M, Tomii K, Sese J . Compound-protein interaction prediction with end-to-end learning of neural networks for graphs and sequences. Bioinformatics. 2018; 35(2):309-318. DOI: 10.1093/bioinformatics/bty535. View

Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y . TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2023; 52(D1):D1465-D1477. PMC: 10767903. DOI: 10.1093/nar/gkad751. View

Wu H, Huang J, Zhong Y, Huang Q . DrugSig: A resource for computational drug repositioning utilizing gene expression signatures. PLoS One. 2017; 12(5):e0177743. PMC: 5451001. DOI: 10.1371/journal.pone.0177743. View

10.

Mi H, Muruganujan A, Ebert D, Huang X, Thomas P . PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2018; 47(D1):D419-D426. PMC: 6323939. DOI: 10.1093/nar/gky1038. View

11.

Azad A, Dinarvand M, Nematollahi A, Swift J, Lutze-Mann L, Vafaee F . A comprehensive integrated drug similarity resource for in-silico drug repositioning and beyond. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa126. View

12.

Chen Y, Diamante G, Ding J, Nghiem T, Yang J, Ha S . PharmOmics: A species- and tissue-specific drug signature database and gene-network-based drug repositioning tool. iScience. 2022; 25(4):104052. PMC: 8957031. DOI: 10.1016/j.isci.2022.104052. View

13.

Zhang Y, Liu X, Li F, Yin J, Yang H, Li X . INTEDE 2.0: the metabolic roadmap of drugs. Nucleic Acids Res. 2023; 52(D1):D1355-D1364. PMC: 10767827. DOI: 10.1093/nar/gkad1013. View

14.

Kandasamy K, Mohan S, Raju R, Keerthikumar S, Sameer Kumar G, Venugopal A . NetPath: a public resource of curated signal transduction pathways. Genome Biol. 2010; 11(1):R3. PMC: 2847715. DOI: 10.1186/gb-2010-11-1-r3. View

15.

Su Y, Wu J, Li X, Li J, Zhao X, Pan B . DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19. Comput Biol Med. 2023; 159:106969. PMC: 10121077. DOI: 10.1016/j.compbiomed.2023.106969. View

16.

Cao Y, Charisi A, Cheng L, Jiang T, Girke T . ChemmineR: a compound mining framework for R. Bioinformatics. 2008; 24(15):1733-4. PMC: 2638865. DOI: 10.1093/bioinformatics/btn307. View

17.

Zhao C, Dai X, Li Y, Guo Q, Zhang J, Zhang X . EK-DRD: A Comprehensive Database for Drug Repositioning Inspired by Experimental Knowledge. J Chem Inf Model. 2019; 59(9):3619-3624. DOI: 10.1021/acs.jcim.9b00365. View

18.

Stathias V, Turner J, Koleti A, Vidovic D, Cooper D, Fazel-Najafabadi M . LINCS Data Portal 2.0: next generation access point for perturbation-response signatures. Nucleic Acids Res. 2019; 48(D1):D431-D439. PMC: 7145650. DOI: 10.1093/nar/gkz1023. View

19.

Chong C, Sullivan Jr D . New uses for old drugs. Nature. 2007; 448(7154):645-6. DOI: 10.1038/448645a. View

20.

Kuhn M, Letunic I, Jensen L, Bork P . The SIDER database of drugs and side effects. Nucleic Acids Res. 2015; 44(D1):D1075-9. PMC: 4702794. DOI: 10.1093/nar/gkv1075. View